全球人類胰島素市場規模、佔有率、成長分析，按類型、應用、分銷管道 - 產業預測，2024-2031 年

2022年全球人類胰島素市場規模為190.5億美元，從2023年的193.7億美元成長到2031年的221.7億美元，預計在預測期間（2024-2031年）年複合成長率為1.7%。

人類胰島素的全球市場受到糖尿病盛行率上升的推動，並在全球糖尿病管理中發揮重要作用。該部門致力於透過生產人類胰島素產品並將其分銷給世界各地的醫療機構、藥房和患者來滿足對胰島素不斷成長的需求。根據國際糖尿病聯盟預測，到 2045 年，診斷出糖尿病的人數將達到 7 億，這正在推動市場擴張。重組 DNA 技術等技術進步正在創造更安全、更有效的胰島素製劑，推動其採用和市場成長。儘管努力改善可近性，胰島素的高成本仍然是一個主要障礙，特別是在低收入地區，受到製造成本上升和監管複雜性的阻礙。從傳統胰島素轉向功效優越的類似胰島素的轉變已成為普遍趨勢，進一步推動了市場成長。此外，對提供便利性和準確性的胰島素輸送設備的需求不斷成長，而連網型設備和人工智慧等新技術正在推動其採用。

目錄

執行摘要

• 市場概況
• 繁榮與衰落

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模估算
• 市場危機與限制

母市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務

主要市場考察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• Start-Ups分析
• 原料分析
• 創新矩陣
• 研發線產品分析
• 總體經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 監管環境
• 波特的分析
• 對未來中斷的特殊考慮

全球人類胰島素市場：按類型

• 市場概況
• 常規人類胰島素和胰島素類似物

人類胰島素的全球市場：依應用分類

• 市場概況
• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

全球人胰島素市場：按分銷管道分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 糖尿病診所

全球人類胰島素市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2021年）
• 主要市場參與者所採取的策略
• 關鍵成功策略
• 近期市集活動
• 主要企業市場佔有率（2021年）

主要企業簡介

• 諾和諾德（丹麥）
• 禮來公司（美國）
• 賽諾菲（法國）
• 默克公司（美國）
• 輝瑞公司（美國）
• 阿斯特捷利康（英國）
• 強生公司（美國）
• Biocon 有限公司（印度）
• Ypsomed AG（瑞士）
• 沃克哈特有限公司（印度）
• Julphar（阿拉伯聯合大公國）
• 甘李藥業（中國）
• Bioton SA（波蘭）
• 阿多西亞（法國）
• Torrent 製藥有限公司（印度）
• 柏林化學股份公司（德國）
• SemBioSys Genetics Inc.（加拿大）
• Biodel 公司（美國）
• 東寶企業集團股份有限公司 (中國)
• 通化東寶藥業有限公司 (中國)

Global Human Insulin Market size was valued at USD 19.05 Billion in 2022 and is poised to grow from USD 19.37 Billion in 2023 to USD 22.17 Billion by 2031, at a CAGR of 1.7% during the forecast period (2024-2031).

The Global Human Insulin Market serves as a vital component in managing diabetes worldwide, propelled by the escalating prevalence of the condition. This sector endeavors to meet the mounting demand for insulin by producing and distributing human insulin products to healthcare facilities, pharmacies, and patients globally. The exponential increase in diabetes diagnoses, projected to reach 700 million by 2045 according to the International Diabetes Federation, fuels the market's expansion. Technological advancements like recombinant DNA technology have yielded safer and more effective insulin products, fostering their adoption and market growth. Despite efforts to enhance accessibility, the high cost of insulin persists as a significant barrier, especially in low-income regions, hindered by elevated production costs and regulatory complexities. Transitioning from traditional to analog insulin, with its superior efficacy, has become a prevalent trend, further propelling market growth. Additionally, there's a rising demand for insulin delivery devices, offering convenience and accuracy, with emerging technologies like connected devices and artificial intelligence driving their adoption.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Insulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Insulin Market Segmental Analysis

Global Human Insulin Market is segmented on the basis of type, application, distribution channel, and region. By type, the market is segmented into traditional human insulin and analog insulin. By application, the market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and diabetes clinics. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Human Insulin Market

The increasing incidence of diabetes globally serves as a major catalyst for the expansion of the worldwide human insulin market. According to the International Diabetes Federation, approximately 463 million adults had diabetes in 2019, a figure anticipated to climb to 700 million by 2045. This burgeoning population of individuals with diabetes creates a greater need for insulin, propelling market growth. For instance, nations such as China and India have experienced a surge in diabetes cases attributable to shifting lifestyles and dietary patterns, consequently driving up the demand for human insulin.

Restraints in the Global Human Insulin Market

Regulatory barriers and patent exclusivity pose significant obstacles in the human insulin market, constraining competition and market entry. Securing regulatory approvals for novel insulin products or biosimilars demands extensive testing and adherence to strict regulations. Furthermore, the exclusivity granted to specific insulin formulations restricts the proliferation of generic alternatives, thereby limiting patient choices and hindering market expansion. Notably, the dominance of certain long-acting insulin analogs under patent protection further impedes the introduction of biosimilar counterparts into the market.

Market Trends of the Global Human Insulin Market

A discernible shift is observed in the market as it moves away from conventional human insulin towards analog insulin, which provides benefits like quicker onset, shorter action duration, and enhanced glycemic control. Healthcare professionals and individuals with diabetes are progressively embracing analog insulin to attain superior management of the condition. Notably, long-acting analog insulin such as insulin glargine (Lantus) and insulin detemir (Levemir) have witnessed substantial market growth owing to their improved pharmacokinetic profiles.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Human Insulin Market by Type

• Market Overview
• Traditional human insulin and analog insulin

Global Human Insulin Market by Application

• Market Overview
• Type 1 diabetes
• type 2 diabetes
• and gestational diabetes

Global Human Insulin Market by Distribution channel

• Market Overview
• Hospital pharmacies
• retail pharmacies
• online pharmacies
• and diabetes clinics

Global Human Insulin Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar (United Arab Emirates)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gan & Lee Pharmaceuticals (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioton S.A. (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adocia (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Berlin-Chemie AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SemBioSys Genetics Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biodel Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dongbao Enterprise Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments